Ildiko Csiki, MD, PhD
Dr. Csiki most recently served as the chief commercial research and development (R&D) officer at City of Hope, an NCI-designated leading cancer center, where she leads the development of a translational biotech-like R&D arm and oversees the research business development and the office of transfer and licensing functions. Previously, Dr. Csikiserved as the chief medical officer at Sensei Biotherapeutics, where she was responsible for the clinical strategy for the discovery and development of cancer immunotherapies. Prior to that, Dr. Csiki served as Vice of President of Immuno-Oncology Clinical Development at Inovio Pharmaceuticals where she led the advancement of Inovio’s DNA-based cancer immunotherapies. She also held clinical development lead roles at Merck responsible for pembrolizumab (Keytruda®) development in multiple indications as well as at GSK focused on multiple assets for various cancer programs. Dr Csiki began her post-graduate career at the University of Pennsylvania, Perelman School of Medicine as a tenure-track physician scientist in the Department of Radiation Oncology. She earned an M.D. and Ph.D. in cancer biology from the Vanderbilt University School of Medicine. Her postdoctoral training included an internship in Internal Medicine and residency in radiation oncology at Vanderbilt and subsequently, a Holman Pathway Research Fellowship. She is also a General Management Program graduate from the Wharton Business School with focus in strategic innovation and entrepreneurship.